Micro-Emulsion Alprostadil Injection
Micro-Emulsion Alprostadil Injectionis ranked as the No. 2 cardiovascular disease treatment measured by Chinese hospital usage, and it has experienced a growth rate of 17% per year (China Pharmaceutical News, 2010). According to the Development Research Centre of the State Council of China, the direct medical cost of cardiovascular disease in China has reached 130 billion RMB per year since 2007 (DRCnet, 2007).
Another Important Top Line Growth Engine
The Company targets launching sales of micro-emulsion alprostadil injection in March 2011. Mr. Zhu XiaoDong, CEO of Dongsheng, stated, "With full control of the technological, sales and manufacturing rights, leveraged with the Company's extensive sales network within China, alprostadil represents an exciting opportunity for Dongsheng to diversify its revenue sources."
About Dongsheng Pharmaceutical International Co., Ltd.
Headquartered in Chengdu, Sichuan Province, China, Dongsheng Pharmaceutical International Co., Ltd. engages in pharmaceutical technology promotion, trading and warehousing of traditional Chinese medicine and bio-chemistry products. The Company sells prescription and non-prescription drugs and provides new medicine research and development and drug registration services distributing to more than 30 provinces in China and throughout Southeast Asia.
Forward-Looking Statements
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements include, but are not limited to, those contained in Dongsheng's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Dongsheng assumes no obligation to update and supplement forward-looking statements because of subsequent events.
For more information, please visit: www.eappic.com | |
Company Contact: | |
Dongsheng Pharmaceutical International Co., Ltd. | |
Ph: 201-898-0688 (US), 8610-88580780 (CHINA) | |
Email: eappic@eappic.com | |
SOURCE Dongsheng Pharmaceutical International Co., Ltd.